Secondary Logo

Journal Logo

Erratum

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials: Erratum

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: July 1, 2020 - Volume 84 - Issue 3 - p e21
doi: 10.1097/QAI.0000000000002394

In the March 1, 2020 issue of JAIDS Journal of Acquired Immune Deficiency Syndromes, in the article titled “Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials,”1 there were errors in Supplementary Digital Content files 3, 4, 5, and 11.

The corrected Supplementary Digital Content files are available in the links below: https://links.lww.com/QAI/B472, https://links.lww.com/QAI/B473, https://links.lww.com/QAI/B474, and https://links.lww.com/QAI/B475.

REFERENCE

1. Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of Dolutegravir Plus lamivudine in antiretroviral treatment–naive Adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical Trials. J Acquir Immune Defic Syndr. 2020;83:310–318.

Supplemental Digital Content

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.